* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download fact sheet
Survey
Document related concepts
Clinical trial wikipedia , lookup
Environmental persistent pharmaceutical pollutant wikipedia , lookup
Pharmacokinetics wikipedia , lookup
MTOR inhibitors wikipedia , lookup
Environmental impact of pharmaceuticals and personal care products wikipedia , lookup
Neuropharmacology wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Neuropsychopharmacology wikipedia , lookup
Drug discovery wikipedia , lookup
Pharmaceutical industry wikipedia , lookup
Prescription costs wikipedia , lookup
Transcript
February 2013 FACT SHEET Ability Pharmaceuticals is a biopharmaceutical company located in Barcelona, Catalonia, Spain. Ability Pharmaceuticals has developed a proprietary new drug class called Lipid Analogue Therapeutics. Ability Pharmaceuticals has two drugs candidates in development in Lung and Pancreatic Cancer: – ABTL0812 in preclinical development with clinical phase Ib/IIa clinical trials (first in man/POC) in lung cancer starting in 2Q 2013 and with pancreatic cancer as a second indication. – ABTL1014 will start preclinical development in 2Q 2013. At a glance – Founded in November 2009 – Focused in Cancer. – mTORC1/C2 - akt -DHFR inhibition – First in Man in 2Q 2013 – 6 Employees – Based in Barcelona, Catalonia, Spain – US Dev. Office in 2013 – € 3.4 M raised (2010-2012): BA, Founders & Inveready Capital Co. Lipid Analogue Therapeutics – A New Drug Class of Cancer Drugs The patent allows the chemical synthesis of thousands of distinct analogues of naturally occurring lipids with variations on chain length, unsaturation level, chemical radicals and salts. Several compounds have been synthesized and evaluated as anticancer drugs. 2 drug candidates have been selected for development. The lipid analogues → influence the activity of proteins which are central to cellular replication. → alter the signaling of specific pathways. ABTL0812. First in Class. Dual Mechanism of Action: mTORC1/C2-DHFR Jordi Espadaler, PhD Senior Scientist & co-Founder 5 years Research at Rockefeller Univ., UC San Francisco & Univ. Autònoma of Barcelona - 5 yrs CSO at AB-Biotics TEAM Experienced Management Team st → Non-small cell lung carcinoma (1 indication) nd → Pancreatic cancers (2 indication) High efficacy Oral administration Low toxicity / Few adverse events Chronic treatment - Once daily Low probability of appearance of drug resistance New drug class – First in class – New product series with the ability to build a development pipeline Simultaneous action on validated targets: DHFR & mTORC1/C2 → Autophagy Possibility of selection of patient populations in clinical trials based on biomarkers Patent protection until 2030 13 yrs Business Dev.t & Licensing at Almirall & Lacer - 3 yrs Biotech VC - 8 yrs Cancer Research Memorial Sloan-Kettering Cancer Center, CSIC & Univ. Autònoma of Barcelona 6 yrs Research at Hebrew Univ. of Jerusalem and Univ. of Barcelona - 12 yrs, drug discovery, drug development (pre-clinical and clinical) at Palau Pharma & Uriach TECHNOLOGY Differentiated treatment in clear unmet medical needs: Carles Domènech, PhD CEO & co-Founder José Alfón, PhD VP Research and Development → Inhibition of DHFR gene expression (dihydrofolate reductase): DNA synthesis. → Inhibition of the mTOR pathway: mTORC1/C2. → Inhibiton of akt phosphorylation. → Cell death by AUTOPHAGY DHFR and mTOR are validated targets in cancer chemotherapy (AlimtaTM, AffinitorTM). KEY VALUES: Management Board of Directors: Has started up biotech and pharma companies and taken them through IPOs and trade sales. Top quality Scientific Advisory Board: → → → → 25+years senior experience in all phases of drug development Managed 3+ FDA-EMA approvals Top level clinical practice First class science High level business advisors Lean HR Building US scientific network Marc Cortal, MD Medical Director Clinical Practice, Clinical Trials, Health Management - Clínica Quirón / Hospital Mutua de Terrassa / Middlesex Hospital / Saint Mary London / Red Cross Geneva Vanessa Ruz, BEc/MEc Director, Administration and Finance Formerly Chief Financial Officer of Sevibe Cells Patent WO2010/106211 – Patent filed in 03/2009 – PCT initiated in 03/2010 – Published in 10/2010 – International phase: 09/2011: AU, BR, CA, CH, CN, EP, IN, IL, JP, KR, MX, RU, ES, US. – Ability Pharmaceuticals, SL Executive Summary© ABTL0812. Action on non-small cell carcinoma and pancreatic cancer in cell and animal models Cell models: Higher inhibition of lung cancer and pancreatic cancer cells in vitro and selective induction of cell death in tumor cells versus fibroblasts. Also active against hepatoma, glioma and melanoma cell lines. Xenografts in immunosuppressed mice: Board of Directors Luis Sánchez-Lafuente - Chairman Chairman of AB Biotics, SA Former CEO and co-owner of Laboratorios Gelos, SA Miquel Àngel Bonachera - Vice Chairman CEO and co- founder of AB Biotics, SA BSc/MSc in biochemistry and MBA Non-small cell lung carcinoma. 4 weeks treatment, oral. 70% reduction of tumor growth and tumor growth arrest in 10% of treated mice. Adverse events (weight loss) markedly lower than in mice treated with docetaxel (Taxotere™). Superiority to erlotinib (Tarceva™) in recent mice studies. Sergi Audivert - Secretary General Dose-dependent tumor response (tumor size and histological markers). Managing General Partner, Inveready Capital Company 140 Control oral Control ip AT12 low oral AT12 high oral 100 Weight Variation (%) Tumor volume (% basal) 120 Docetaxel ip 80 60 40 20 n=1 n=1 n=2 0 0 5 10 15 20 25 30 Day 15 General Partner, Inveready Capital Company 10 Carles Domènech, PhD 5 CEO, Ability Pharmaceuticals, SL 0 José Manuel Valadés -5 Lawyer, partner and founder of the law firm Alliant -10 Control oral -15 n=1 Control ip -20 AT12 low oral -25 AT12 high oral Scientific Advisory Board n=1 n=2 Docetaxel ip -30 35 Josep M. Echarry Roger Piqué AT12 vs. docetaxel, body weight AT12 vs. docetaxel, tumor volume CEO and co-founder of AB Biotics, SA BSc/MSc in food technology and MBA 0 5 10 15 20 25 30 35 Toni Pérez, MD Chairman of the Board - Clinical Development Day Pancreatic cancer. 4 weeks treatment, oral. Efficacy equal to gemcitabine (iv). Absence of adverse events. An advantage over gemcitabine is that there is no oral formulation of this marketed drug. Formerly Medical Director at Esteve, Almirall, Novartis and Basilea Pharmaceuticals Peter Wyld, MD Clinical Development Formerly Medical Director at Biogen, Amgen and J&J Oncologicals Business Model The company will develop new drug candidates up through clinical proof of concept, and will then out-license them to biopharmaceutical companies for further development. The company begins discussions with potential partners early in the development phase to interest them early and then to keep them involved with timely updates. Laura Vidal, MD, Clinical Oncology Coordinator, Investigational Therapy Unit - Oncology and Hematology, IDIBAPS and Hospital Clínic de Barcelona Universitat de Barcelona Jesús Llenas, PhD Preclinical Development Formerly Head of Pharmacology at Almirall ABTL0812. Preclinical development → Good DMPK properties in rat and dog (long half life and high oral bioavailability). → Very safe up to high does (acute and chronic). → Rat and dog 28d GLPtox → 7 Kg of GMP of API produced. → Formulation under development. → IMPD in preparation José Luís Fábregas, PhD ABTL0812 is highly differentiated from over 300+ drugs in development for Lung Cancer. Broad range efficacy vs. reduced sub-populations ABTL0812. Clinical Plan Market and Treatment Phase Ib/IIa (First in Man/Proof of Concept) in non-small cell lung carcinoma (NSCLC) planned for 2Q 2013. Multiple ascending dose trial. Multicenter. Enrollment 1.5 years. Lung cancer accounts for 12% of all cancers and is responsible for over 30% of all cancer deaths. 1 year survival: 42%. 5 years survival: 15%. Phase Ib: determination of the recommended dose-limiting toxicity in patients with advanced cancer. 27 patients. 9 months. NSCLC accounts for 25% of cancer drug sales. Current treatment has ignificant side-effects: cisplatin, docetaxel, erlotinib, gemcitabine. Phase IIa: determination of the dose, schedule and response rate. ABTL0812 in combination with standard of care. 40 patients. Pancreatic cancer holds the 6th position as cause of cancer death. 2 years survival: 5% Current treatment: erlotinib and gemcitabine. Poor long term efficacy. Pharmaceutical Development Formerly Senior Director of Pharmaceutical Dev. at Almirall José Miguel Lizcano, PhD Signal Transduction Professor at Univ. Autònoma of Barcelona, formerly at Philip Cohen’s Laboratory, Univ. of Dundee ABTL0812 is expected to reach sales over $ 2 Billion 7 years after launch Contact For further information on Ability Pharmaceuticals and its products, please visit www.abilitypharma.com or contact: Carles Domènech, PhD Chief Executive Officer T: +34 935 868 977 C: +34 606 433 824 Skype: carles.domenech E: carles.domenech@ abilitypharma.com Ability Pharmaceuticals, SL Edifici Eureka - Campus de la UAB 08193 Bellaterra (Barcelona) Catalonia – Spain Proprietary Information belonging exclusively to Ability Pharmaceuticals, SL ©